| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Chains in Tumor-infiltrating T-Cells and NK Cells of Patients with Colorectal Carcinoma1Microbiology and Tumor Biology Center, Laboratory of Immunology, Karolinska Institute [H. N., M. P., M. M., R. K.]; Department of Surgery, Södersjukhuset [I. M., H. M.]; Radiumhemmet, Karolinska sjukhuset [I. M., H. M.], Stockholm, Sweden; Department of Surgery, Akademiska sjukhuset, Uppsala, Sweden [C. J.]; and Dana Farber Cancer Institute, Boston, Massachusetts 02115 [J-L. T., E. V., P. A.]
2 To whom requests for reprints should be addressed, at Dept. of Immunology, Karolinska institute, S-171 77 Stockholm, Sweden.
An impaired immune response is frequently observed in cancer patients and tumor-bearing mice. T-cells from mice with an experimental colon carcinoma were recently shown to express T-cell receptors that completely lacked the signal-transducing molecule CD3 
. Here, we have investigated the expression of the signal-transducing molecule on lymphocytes from 14 patients with colorectal carcinomas using flow cytometric analysis of permeabilized cells with a monoclonal antibody (TIA-2; IgG1) specific for the cytoplasmic domain of the chain as well as with immunoprecipitation and analysis on diagonal gel electrophoresis. We demonstrate that T-cells isolated from the tumors of the patients express significantly less CD3 than T-cells in the peripheral blood of the same patients and that the peripheral blood of the patients express decreased levels of chains, as compared to the levels found in lymphocytes from healthy controls. This decreased expression was also observed on chains associated with the low affinity Fc receptor for IgG found in tumor-infiltrating NK cells (Fc
RIIIA
; CD16).
1 This work was supported by grants from the Swedish Cancer Society and from the Cancer Society in Stockholm. M. M. is the recipient of a fellowship from the Wenner-Grenska samfundet (Wennergren Foundation), Stockholm, Sweden.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 8/19/93. Accepted 10/20/93.
This article has been cited by other articles:
|
|
 |
|
  A. Das, M. Hoare, N. Davies, A. R. Lopes, C. Dunn, P. T.F. Kennedy, G. Alexander, H. Finney, A. Lawson, F. J. Plunkett, et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection J. Exp. Med., September 1, 2008; 205(9): 2111 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells Blood, October 1, 2007; 110(7): 2537 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, C. L. Gorman, A.-C. Vermi, C. Monaco, A. Foey, S. Owen, P. Amjadi, A. Vallance, C. McClinton, F. Marelli-Berg, et al. TCR{zeta}dimlymphocytes define populations of circulating effector cells that migrate to inflamed tissues Blood, May 15, 2007; 109(10): 4328 - 4335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood, May 1, 2007; 109(9): 3812 - 3819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jewett, C. Head, and N.A. Cacalano Emerging Mechanisms of Immunosuppression in Oral Cancers Journal of Dental Research, December 1, 2006; 85(12): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Ezernitchi, I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. Pikarsky, L. Shapira, and M. Baniyash TCR {zeta} Down-Regulation under Chronic Inflammation Is Mediated by Myeloid Suppressor Cells Differentially Distributed between Various Lymphatic Organs J. Immunol., October 1, 2006; 177(7): 4763 - 4772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Takahashi, M. G. V. Hanson, H. R. Norell, A. M. Havelka, K. Kono, K.-J. Malmberg, and R. V. R. Kiessling Preferential Cell Death of CD8+ Effector Memory (CCR7-CD45RA-) T Cells by Hydrogen Peroxide-Induced Oxidative Stress J. Immunol., May 15, 2005; 174(10): 6080 - 6087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Yu, Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber, and Y.-X. Fu Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors J. Exp. Med., March 7, 2005; 201(5): 779 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Kim, T. M. Stringfield, Y. Chen, and H. E. Broxmeyer Modulation of cord blood CD8+ T-cell effector differentiation by TGF-{beta}1 and 4-1BB costimulation Blood, January 1, 2005; 105(1): 274 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance Cancer Res., April 15, 2004; 64(8): 2865 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Sakkas, G. Koussidis, E. Avgerinos, J. Gaughan, and C. D. Platsoucas Decreased Expression of the CD3{zeta} Chain in T Cells Infiltrating the Synovial Membrane of Patients with Osteoarthritis Clin. Vaccine Immunol., January 1, 2004; 11(1): 195 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnan, D. L. Farber, and G. C. Tsokos T Cell Rewiring in Differentiation and Disease J. Immunol., October 1, 2003; 171(7): 3325 - 3331. [Full Text] [PDF]
|
|
|
|
|
|
Y. Lu, Y.-q. Wei, L. Tian, X. Zhao, L. Yang, B. Hu, B. Kan, Y.-j. Wen, F. Liu, H.-x. Deng, et al. Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor J. Immunol., March 15, 2003; 170(6): 3162 - 3170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Schaft, R. A. Willemsen, J. de Vries, B. Lankiewicz, B. W. L. Essers, J.-W. Gratama, C. G. Figdor, R. L. H. Bolhuis, R. Debets, and G. J. Adema Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCR{alpha}{beta} Genes Into Primary Human T Lymphocytes J. Immunol., February 15, 2003; 170(4): 2186 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation J. Immunol., November 15, 2002; 169(10): 5780 - 5786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Somasundaram, L. Jacob, R. Swoboda, L. Caputo, H. Song, S. Basak, D. Monos, D. Peritt, F. Marincola, D. Cai, et al. Inhibition of Cytolytic T Lymphocyte Proliferation by Autologous CD4+/CD25+ Regulatory T Cells in a Colorectal Carcinoma Patient Is Mediated by Transforming Growth Factor-{beta} Cancer Res., September 15, 2002; 62(18): 5267 - 5272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Wieckowski, G.-Q. Wang, B. R. Gastman, L. A. Goldstein, and H. Rabinowich Granzyme B-mediated Degradation of T-Cell Receptor {zeta} Chain Cancer Res., September 1, 2002; 62(17): 4884 - 4889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chames, R. A. Willemsen, G. Rojas, D. Dieckmann, L. Rem, G. Schuler, R. L. Bolhuis, and H. R. Hoogenboom TCR-Like Human Antibodies Expressed on Human CTLs Mediate Antibody Affinity-Dependent Cytolytic Activity J. Immunol., July 15, 2002; 169(2): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cemerski, A. Cantagrel, J. P. M. van Meerwijk, and P. Romagnoli Reactive Oxygen Species Differentially Affect T Cell Receptor-signaling Pathways* J. Biol. Chem., May 24, 2002; 277(22): 19585 - 19593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Y. Shibuya, N. Nugyen, C. E. McLaren, K.-T. Li, W.-Z. Wei, S. Kim, G. H. Yoo, A. Rogowski, J. Ensley, and W. Sakr Clinical Significance of Poor CD3 Response in Head and Neck Cancer Clin. Cancer Res., March 1, 2002; 8(3): 745 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance J. Exp. Med., February 11, 2002; 195(4): 423 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnan, V. G. Warke, M. P. Nambiar, H. K. Wong, G. C. Tsokos, and D. L. Farber Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3{zeta} expression Blood, June 15, 2001; 97(12): 3851 - 3859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schmielau and O. J. Finn Activated Granulocytes and Granulocyte-derived Hydrogen Peroxide Are the Underlying Mechanism of Suppression of T-Cell Function in Advanced Cancer Patients Cancer Res., June 1, 2001; 61(12): 4756 - 4760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Y. Woo, C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June Regulatory CD4+CD25+ T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer Cancer Res., June 1, 2001; 61(12): 4766 - 4772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Takahashi, K. Kono, H. Amemiya, H. Iizuka, H. Fujii, and Y. Matsumoto Elevated Caspase-3 Activity in Peripheral Blood T Cells Coexists with Increased Degree of T-Cell Apoptosis and Down-Regulation of TCR Zeta Molecules in Patients with Gastric Cancer Clin. Cancer Res., January 1, 2001; 7(1): 74 - 80. [Abstract] [Full Text]
|
|
|
|
|
|
I. Borrello, E. M. Sotomayor, F.-M. Rattis, S. K. Cooke, L. Gu, and H. I. Levitsky Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines Blood, May 15, 2000; 95(10): 3011 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Radoja, T. D. Rao, D. Hillman, and A. B. Frey Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo J. Immunol., March 1, 2000; 164(5): 2619 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ito, K. Ogasawara, K. Iwabuchi, Y. Inuyama, and K. Onoe Induction of CTL Responses by Simultaneous Administration of Liposomal Peptide Vaccine with Anti-CD40 and Anti-CTLA-4 mAb J. Immunol., February 1, 2000; 164(3): 1230 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Kwon, B. A. Foster, A. A. Hurwitz, C. Madias, J. P. Allison, N. M. Greenberg, and M. B. Burg Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy PNAS, December 21, 1999; 96(26): 15074 - 15079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maccalli, P. Pisarra, C. Vegetti, M. Sensi, G. Parmiani, and A. Anichini Differential Loss of T Cell Signaling Molecules in Metastatic Melanoma Patients' T Lymphocyte Subsets Expressing Distinct TCR Variable Regions J. Immunol., December 15, 1999; 163(12): 6912 - 6923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bronstein-Sitton, L. Wang, L. Cohen, and M. Baniyash Expression of the T Cell Antigen Receptor zeta Chain following Activation Is Controlled at Distinct Checkpoints. IMPLICATIONS FOR CELL SURFACE RECEPTOR DOWN-MODULATION AND RE-EXPRESSION J. Biol. Chem., August 13, 1999; 274(33): 23659 - 23665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Reisser, L. Arnould, M. Maynadie, C. Belichard, B. Coudert, and J.-F. Jeannin Lipid A OM-174 increases the natural killer activity of peripheral blood cells from breast cancer patients Innate Immunity, August 1, 1999; 5(4): 189 - 195. [Abstract] [PDF]
|
|
|
|
 |
|
 T.R.J. Evans and S.B. Kaye Vaccine therapy for cancer—fact or fiction? QJM, June 1, 1999; 92(6): 299 - 307. [Full Text] [PDF]
|
|
|
|
|
|
S. Horiguchi, M. Petersson, T. Nakazawa, M. Kanda, A. H. Zea, A. C. Ochoa, and R. Kiessling Primary Chemically Induced Tumors Induce Profound Immunosuppression Concomitant with Apoptosis and Alterations in Signal Transduction in T Cells and NK Cells Cancer Res., June 1, 1999; 59(12): 2950 - 2956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saito, I. Kuss, G. Dworacki, W. Gooding, J. T. Johnson, and T. L. Whiteside Spontaneous ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Head and Neck Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1263 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Gastman, D. E. Johnson, T. L. Whiteside, and H. Rabinowich Caspase-mediated Degradation of T-Cell Receptor {{zeta}}-Chain Cancer Res., April 1, 1999; 59(7): 1422 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kuss, T. Saito, J. T. Johnson, and T. L. Whiteside Clinical Significance of Decreased {{zeta}} Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer Clin. Cancer Res., February 1, 1999; 5(2): 329 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Clay, M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue J. Immunol., February 1, 1999; 162(3): 1749 - 1755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Robertson, C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer Clin. Cancer Res., January 1, 1999; 5(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M TODRYK, H CHONG, R G VILE, H PANDHA, and N R LEMOINE Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut, October 1, 1998; 43(4): 445 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ling, P. Rayman, R. Uzzo, P. Clark, H. J. Kim, R. Tubbs, A. Novick, R. Bukowski, T. Hamilton, and J. Finke Impaired Activation of NFkappa B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, Ikappa Balpha Blood, August 15, 1998; 92(4): 1334 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky Induction of antigen-specific T cell anergy: An early event in the course of tumor progression PNAS, February 3, 1998; 95(3): 1178 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Zea, M. T. Ochoa, P. Ghosh, D. L. Longo, W. G. Alvord, L. Valderrama, R. Falabella, L. K. Harvey, N. Saravia, L. H. Moreno, et al. Changes in Expression of Signal Transduction Proteins in T Lymphocytes of Patients with Leprosy Infect. Immun., February 1, 1998; 66(2): 499 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fitzer-Attas, D. G. Schindler, T. Waks, and Z. Eshhar Harnessing Syk Family Tyrosine Kinases as Signaling Domains for Chimeric Single Chain of the Variable Domain Receptors: Optimal Design for T Cell Activation J. Immunol., January 1, 1998; 160(1): 145 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yi, S. Dabadghao, A. Osterborg, S. Bergenbrant, and G. Holm Myeloma Bone Marrow Plasma Cells: Evidence for Their Capacity as Antigen-Presenting Cells Blood, September 1, 1997; 90(5): 1960 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wick, P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy J. Exp. Med., July 21, 1997; 186(2): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Schultze, M. J. Seamon, S. Michalak, J. G. Gribben, and L. M. Nadler Autologous Tumor Infiltrating T Cells Cytotoxic for Follicular Lymphoma Cells Can Be Expanded In Vitro Blood, May 15, 1997; 89(10): 3806 - 3816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Saxton, D. L. Longo, H. E. Wetzel, H. Tribble, W. G. Alvord, L. W. Kwak, A. S. Leonard, C. D. Ullmann, B. D. Curti, and A. C. Ochoa Adoptive Transfer of Anti-CD3-Activated CD4+ T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity Blood, April 1, 1997; 89(7): 2529 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Guarini, L. Riera, A. Cignetti, L. Montacchini, M. Massaia, and R. Foa Transfer of the Interleukin-2 Gene Into Human Cancer Cells Induces Specific Antitumor Recognition and Restores the Expression of CD3/T-Cell Receptor Associated Signal Transduction Molecules Blood, January 1, 1997; 89(1): 212 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rodriguez-Tarduchy, A. G. Sahuquillo, B. Alarcon, and R. Bragado Apoptosis but Not Other Activation Events Is Inhibited by a Mutation in the Transmembrane Domain of T Cell Receptor beta That Impairs CD3zeta Association J. Biol. Chem., November 29, 1996; 271(48): 30417 - 30425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Otsuji, Y. Kimura, T. Aoe, Y. Okamoto, and T. Saito Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses PNAS, November 12, 1996; 93(23): 13119 - 13124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hellstrom, J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellstrom CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer PNAS, June 5, 2001; 98(12): 6783 - 6788. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
